TL;DR
- Former investment banker Gyunho “Justin” Kim allegedly tipped a friend, Muhammad Saad Shoukat, with confidential details on at least nine pharmaceutical and healthcare acquisitions.
- Saad Shoukat allegedly passed the tips to his brothers and two other friends, generating roughly $41 million in combined trading profits from June 2020 to February 2024.
- The most profitable trade centered on Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics.
- Two of the Shoukat brothers separately ran market manipulation schemes against Olema Pharmaceuticals and Opiant Pharmaceuticals, including a fabricated $225 million “acquisition” press release.
- Six defendants face overlapping SEC civil charges and DOJ criminal charges; Kim has since been barred from the securities industry by FINRA.
According to SEC and DOJ filings, Kim worked in the healthcare mergers-and-acquisitions group of a major investment bank’s San Francisco office. Between June 2020 and February 2024, prosecutors allege he repeatedly passed confidential deal intelligence — obtained through internal communications, virtual data rooms, and deal documents — to his close friend, Muhammad Saad Shoukat.
Saad, in turn, allegedly relayed the tips to his brothers, Muhammad Arham Shoukat and Muhammad Shahwaiz Shoukat, as well as to two additional friends, Izunna Okonkwo and Daniyal Khan, who traded on the information.
What Kim Allegedly Got in Return
The SEC’s complaint alleges Kim received personal benefits in exchange for the tips, including a Rolex watch, career advice, and help editing a confidential work project — details prosecutors have used to establish the kind of personal quid pro quo required to sustain an insider trading charge under U.S. securities law.
The Deals Involved
Prosecutors say the scheme touched at least nine corporate acquisitions in the healthcare and pharmaceutical space, including Gilead Sciences’ $21 billion purchase of Immunomedics, CVS Health’s $10.6 billion acquisition of Oak Street Health, and AbbVie’s $10.1 billion purchase of ImmunoGen — three of the largest healthcare deals the bank advised on over the past decade.
The complaint also cites trading tied to Aimmune Therapeutics, Five Prime Therapeutics, Adamas Pharmaceuticals, Sierra Oncology, and Reata Pharmaceuticals.
The Global Blood Therapeutics Trade
The single most profitable trade in the scheme, according to court filings, involved Global Blood Therapeutics, a company developing treatments for sickle-cell disease.
Kim’s employer represented an unidentified client examining a potential acquisition of Global Blood Therapeutics in 2022; Kim reportedly worked on a detailed financial analysis of the target that April, and the Shoukat group began building stock positions the following month.
When news of takeover interest broke and Global Blood Therapeutics’ stock rose, the group sold its position for a reported $20 million in profit. Pfizer ultimately acquired the company for $5.4 billion.
A Second Front: Market Manipulation
The insider trading scheme was only part of the case. The SEC separately alleges that Saad and Arham Shoukat manipulated the stock of Olema Pharmaceuticals in 2021 by impersonating physicians and metastatic breast cancer patients online — including through spoofed email accounts mimicking Texas Oncology, Roswell Park Comprehensive Cancer Center, and Ackerman Cancer Center — to obtain and then falsify confidential clinical trial data, netting Saad and Arham a combined $257,962.
The Fake Opiant Acquisition
In a third alleged scheme, Kim tipped Saad that another company was seeking to acquire Opiant Pharmaceuticals, developer of an opioid overdose treatment. When that deal stalled, the SEC alleges the Shoukat brothers registered a fake corporate domain and created imposter executive email accounts to distribute a fabricated April 2022 press release claiming Opiant had signed a $225 million deal with Hikma Pharmaceuticals.
The fake news, distributed over Cision PR Newswire, drove a 29% intraday spike in Opiant’s stock before Nasdaq halted trading and both companies publicly denied any agreement. The brothers sold into the spike for combined gains of roughly $372,000, at an estimated cost to other investors of about $1 million.
Charges and Consequences
The SEC filed its complaint in the U.S. District Court for the District of New Jersey on December 22, 2025, charging the Shoukat brothers with violating the Securities Act’s anti-fraud provisions and all six defendants with violating Section 10(b) of the Exchange Act.
Saad and Arham Shoukat face 11 criminal charges apiece between the two schemes, with a combined maximum exposure of up to 195 years in prison. Kim was charged separately and made his initial court appearance in mid-December 2025; he has since been barred from the securities industry by FINRA after refusing to cooperate with a related regulatory document request. The Shoukat brothers have retained former New Jersey governor Chris Christie as counsel.
Why It Matters
The case illustrates how a single leak point inside a bank’s healthcare advisory practice can ripple across a decade of unrelated pharmaceutical transactions, and how modern insider trading rings increasingly blend classic tipping schemes with active disinformation campaigns designed to move a stock price directly rather than simply trade ahead of real news.
Compliance teams at both investment banks and biopharma issuers have cited the case as a reminder to monitor not just internal information barriers, but external chatter — fake press releases, spoofed domains, and impersonated medical professionals — that can move share prices within hours.